Givinostat is a pan-HDAC inhibitor with activity against class I and II histone deacetylases, designed to modulate epigenetic dysregulation and inflammatory signaling in myeloproliferative neoplasms (MPNs). This evidence concerns the gene HDAC9 and myeloproliferative disorder.